GeneDx (WGS) Form 4/A: Casdin updates stake, fixes share counts
Rhea-AI Filing Summary
GeneDx Holdings (WGS) – Amended Form 4 (filed 08-07-25)
Director and 10 % owner Eli Casdin reported the vesting and immediate settlement of 12,924 RSUs on 06-18-25, converting to Class A common shares at $0 exercise cost. Following the event, Casdin now holds 20,518 shares directly and, through various affiliated entities, 3.86 million shares indirectly (3,507,164 via Casdin Partners Master Fund LP, 333,144 via CMLS Holdings LLC, and 19,247 via Casdin Partners GP LLC).
The amendment corrects prior clerical errors: earlier filings over-stated direct holdings by 1,376 shares and under-stated them by 4,452 shares in separate periods. No open-market purchases or sales occurred; transactions solely reflect RSU vesting. The RSUs will continue to vest on the earlier of the next annual meeting or one-year anniversary, contingent on service.
Investor takeaway: The filing increases disclosure accuracy but does not involve cash transactions or alter the overall economic exposure of this significant insider.
Positive
- Insider maintains significant ownership (≈3.9 M shares), indicating continued alignment with shareholders.
- Amendment increases transparency by correcting prior share-count inaccuracies.
Negative
- Repeated clerical errors in previous filings may signal weaknesses in internal compliance processes.
Insights
TL;DR: Clerical fixes and RSU vesting; minimal market impact.
The amendment primarily rectifies share-count errors, enhancing filing accuracy but leaving the insider’s economic stake essentially unchanged. The 12,924-share RSU conversion is routine compensation and cash-neutral. With roughly 3.9 million shares under control, Casdin remains a key long-term holder, which can be interpreted as alignment with shareholder interests. However, repeated clerical mistakes raise minor concerns about internal reporting controls. Given the absence of open-market buying or selling, we view the disclosure as governance-neutral for valuation purposes.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Stock Unit | 3,576 | $0.00 | -- |
| Exercise | Restricted Stock Unit | 12,924 | $0.00 | -- |
| Exercise | Class A Common Stock | 12,924 | $0.00 | -- |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
Footnotes (1)
- Due to clerical errors in prior filings, (i) the number of Class A Common Shares held directly by Eli Casdin was overstated by 1,376 shares in Form 4 filings filed from March 6th, 2024 through June 5th, 2024; and (ii) the Form 4 filed on August 5, 2024 understated Mr. Casdin's direct Class A Common Share holdings by 4,452 shares, as it did not reflect the correct total of 7,594 shares held directly following the vesting of 5,828 RSUs on June 20, 2024. These discrepancies in Class A Common Shares held by Eli Casdin have been corrected in subsequent filings. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. The securities are owned directly by the Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. The securities are owned directly by the GP and may be deemed to be indirectly beneficially owned by Eli Casdin, the managing member of the GP. The securities are owned directly by CMLS Holdings LLC ("CMLS Holdings"). The Board of Managers of CMLS Holdings includes Eli Casdin, who, as a member of the Board of Managers of CMLS Holdings, shares voting and investment discretion with respect to the common stock held by CMLS Holdings. The RSUs shall vest the earlier of (a) the date of the next annual meeting of the Issuer's shareholders following the grant date, and (b) the first anniversary of the grant date, subject to the Reporting Person continuing to provide services to the Issuer through each vesting date.
